Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Increase in Short Interest

Key Points

• Bavarian Nordic experienced a significant increase in short interest in August, rising 250.0% from July, with a total of 700 shares reported.
• The company's latest quarterly earnings indicate a profit of $0.23 EPS, along with a net margin of 21.95% and revenue of $251.14 million.
• As of the latest report, Bavarian Nordic's stock is priced at $12.26, with a 52-week range from a low of $6.60 to a high of $12.98.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totaling 700 shares, anincreaseof250.0% from the July 31st total of 200 shares. Based on an average trading volume of 17,800 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 17,800 shares, the days-to-cover ratio is currently 0.0 days.

Bavarian Nordic Trading Up 0.6%

OTCMKTS:BVNRY traded up $0.07 on Friday, hitting $12.31. 4,868 shares of the company's stock traded hands, compared to its average volume of 4,502. Bavarian Nordic has a 1 year low of $6.60 and a 1 year high of $12.50. The firm has a 50-day moving average price of $11.18 and a 200-day moving average price of $9.16. The company has a market cap of $2.91 billion, a PE ratio of 14.15 and a beta of 1.30.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings results on Friday, August 22nd. The company reported $0.23 EPS for the quarter. The business had revenue of $251.14 million during the quarter. Bavarian Nordic had a return on equity of 12.75% and a net margin of 21.95%. On average, research analysts forecast that Bavarian Nordic will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.